Stock KTTA PASITHEA THERAPEUTICS CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Pasithea Therapeutics Corp.

Equities

KTTA

US70261F2020

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-04-25 pm EDT 		5-day change 1st Jan Change
7.24 USD +4.17% Intraday chart for Pasithea Therapeutics Corp. +1.83% -2.16%
Apr. 24 Pasithea Therapeutics Corp. Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated Cancers CI
Mar. 29 Pasithea Therapeutics Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers
AQ
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004
AQ
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004, Establishes Strengthened Intellectual Property Position
AQ
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position
AQ
Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients
AQ
Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023
AQ
Pasithea Therapeutics Announces Results from 2023 Annual Meeting
AQ
Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models
AQ
Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
AQ
Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development
AQ
Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets 51 Integrin for the Treatment of both Sporadic and Familial ALS
AQ
Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS
AQ
Pasithea Therapeutics : Investor Presentation
PU
Pasithea Therapeutics Corp. Announces Final Results of Tender Offer
AQ
Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference
AQ
Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences that shows an increase in 5 integrin expression in ALS human and mouse brain tissue
AQ
Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved survival and motor function
AQ
Pasithea Therapeutics : Failure to Satisfy Listing Rule - Form 8-K
PU
Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash
AQ
Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KTTA Stock
  4. News Pasithea Therapeutics Corp.
  5. Press Releases